ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200 - Yahoo Finance

1 year ago 39

Drs. Daniel C. Cattran and Fernando C. Fervenza articulation ZyVersa's distinguished radical of Scientific Advisors
VAR 200 is simply a signifier 2a-ready cholesterin efflux mediator successful improvement to ameliorate renal lipid accumulation that damages the kidneys' filtration system, starring to progression of kidney disease

, /PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a objective signifier specialty biopharmaceutical institution processing first-in-class drugs for attraction of renal and inflammatory diseases, announces that 2 starring nephrologists person joined ZyVersa's Renal Scientific Advisory Board.

(PRNewsfoto/Variant Pharmaceuticals, Inc.)

Two esteemed nephrologists articulation ZyVersa's Renal Scientific Advisory Board, Drs. Daniel C. Cattran & Fernando C. Fervenza

Daniel C. Cattran, MD
Professor of Medicine, University of Toronto
Senior Scientist, Toronto General Research Institute

Fernando C. Fervenza, MD, PhD
Professor of Medicine, Mayo Graduate School of Medicine
Director of the Nephrology Collaborative Group

"We are honored that nephrologists with the accomplishments of Drs. Cattran and Fervenza are joining our Scientific Advisory Board," stated Dr. Pablo Guzman, ZyVersa's Chief Medical Officer, and Chairman of the Renal Scientific Advisory Board. "Their objective and probe expertise person earned them planetary favoritism arsenic cardinal thought-leaders successful the tract of nephrology. We look guardant to their invaluable contributions that volition assistance thrust the timely occurrence of our objective improvement programme for our cholesterin efflux mediator, VAR 200," continued Dr. Guzman.

Drs. Cattran and Fervenza articulation ZyVersa's existent squad of salient Scientific Advisors, Sharon G. Adler, MD: Professor of Medicine astatine David Geffen School of Medicine, UCLA; Chief, Division of Nephrology and Hypertension astatine Harbor-UCLA Medical Center; and Program Director, Nephrology Fellowship Training Program astatine Harbor-UCLA Medical Center; Alessia Fornoni, MD, PhD: Professor of Medicine and Chief of Katz Family Division of Nephrology and Hypertension astatine University of Miami Miller School of Medicine; Debbie S. Gipson, MD, MS: Professor, Department of Pediatrics astatine University of Michigan and Director of the Kidney Research Network Coordinating Center; Marlene Haffner, MD, MPH: Principal and Founder of Orphan Solutions and erstwhile Director of Orphan Products Development astatine FDA; and Pablo A. Guzman, MD, FAAC: Chief Medical Officer and Chairman of Renal Scientific Advisory Board astatine ZyVersa Therapeutics.

"Enlisting the insights and strategical guidance of our renowned technological advisory committee is cardinal to achieving our ngo to make transformative cause therapies for patients with renal disease," said Stephen C. Glover, ZyVersa's Co-founder, Chief Executive Officer, and Chairman. "We admit their expertise and clip to enactment our mission," added Mr. Glover.

About VAR 200

VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is simply a cholesterin efflux mediator successful improvement to ameliorate renal lipid accumulation that damages the kidneys' filtration system, starring to kidney illness progression. VAR 200 passively and actively removes excess lipids from the kidney.

Preclinical studies with VAR 200 successful carnal models of FSGS, Alport syndrome, and diabetic kidney illness show that removal of excess cholesterin and lipids from kidney podocytes protects against structural harm and reduces excretion of macromolecule successful the urine (proteinuria).

The pb denotation for VAR 200 is orphan kidney illness focal segmental glomerulosclerosis (FSGS). VAR 200 has imaginable to dainty different glomerular diseases, including orphan Alport syndrome and diabetic kidney disease.

About ZyVersa Therapeutics, Inc.

ZyVersa is simply a objective signifier specialty biopharmaceutical institution leveraging advanced, proprietary technologies to make first-in-class drugs. Our absorption is connected patients with renal oregon inflammatory diseases who person important unmet aesculapian needs. Our improvement pipeline includes signifier 2a-ready VAR 200, a cholesterin efflux mediator successful improvement to alleviate damaging accumulation of cholesterin and lipids successful the filtering strategy of the kidneys. The pb denotation is attraction of uncommon kidney disease, focal segmental glomerulosclerosis. VAR 200 has imaginable to dainty different kidney diseases, including Alport syndrome and diabetic kidney disease. Our pipeline besides includes a proprietary inflammasome ASC inhibitor that blocks initiation and perpetuation of damaging inflammation associated with a multitude of inflammatory diseases. IC 100 has imaginable to dainty galore antithetic CNS and different inflammatory diseases. For much information, delight sojourn www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained successful this property merchandise regarding matters that are not humanities facts, are forward-looking statements wrong the meaning of Section 21E of the Securities Exchange Act of 1934, arsenic amended, and the Private Securities Litigation Reform Act of 1995. These see statements regarding management's intentions, plans, beliefs, expectations, oregon forecasts for the future, and, therefore, you are cautioned not to spot undue reliance connected them. No forward-looking connection tin beryllium guaranteed, and existent results whitethorn disagree materially from those projected. ZyVersa Therapeutics, Inc ("ZyVersa") uses words specified arsenic "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and akin expressions to place these forward-looking statements that are intended to beryllium covered by the safe-harbor provisions. Such forward-looking statements are based connected ZyVersa's expectations and impact risks and uncertainties; consequently, existent results whitethorn disagree materially from those expressed oregon implied successful the statements owed to a fig of factors, including ZyVersa's plans to make and commercialize its merchandise candidates, the timing of initiation of ZyVersa's planned preclinical and objective trials; the timing of the availability of information from ZyVersa's preclinical and objective trials; the timing of immoderate planned investigational caller cause exertion oregon caller cause application; ZyVersa's plans to research, develop, and commercialize its existent and aboriginal merchandise candidates; the objective utility, imaginable benefits and marketplace acceptance of ZyVersa's merchandise candidates; ZyVersa's commercialization, selling and manufacturing capabilities and strategy; ZyVersa's quality to support its intelligence spot position; and ZyVersa's estimates regarding aboriginal revenue, expenses, superior requirements and request for further financing.

New factors look from time-to-time, and it is not imaginable for ZyVersa to foretell each specified factors, nor tin ZyVersa measure the interaction of each specified origin connected the concern oregon the grade to which immoderate factor, oregon operation of factors, whitethorn origin existent results to disagree materially from those contained successful immoderate forward-looking statements. Forward-looking statements included successful this property merchandise are based connected accusation disposable to ZyVersa arsenic of the day of this property release. ZyVersa disclaims immoderate work to update specified forward-looking statements to bespeak events oregon circumstances aft the day of this property release, but arsenic required by applicable law.

This property merchandise does not represent an connection to sell, oregon the solicitation of an connection to buy, immoderate securities.